Eptinezumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | CALCA, CALCB |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6352H9838N1694O1992S46 |
| Molar mass | 143.2 g/mol g·mol−1 |
Eptinezumab (formerly ALD403[1]) is an experimental drug being developed by Alder Biopharmaceuticals for the treatment of migraine. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta.[2][3] It is in Phase III clinical trials as of August 2017[update].[4]
See also
- Other anti-migraine antibodies blocking the CGRP pathway
References
- ^ http://investor.alderbio.com/releasedetail.cfm?releaseid=1001091
- ^ Dodick, David W; Goadsby, Peter J; Silberstein, Stephen D; Lipton, Richard B; Olesen, Jes; Ashina, Messoud; Wilks, Kerri; Kudrow, David; Kroll, Robin; Kohrman, Bruce; Bargar, Robert; Hirman, Joe; Smith, Jeff (2014). "Safety and efficacy of eptinizumab, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: A randomised, double-blind, placebo-controlled, exploratory phase 2 trial". The Lancet Neurology. 13 (11): 1100. doi:10.1016/S1474-4422(14)70209-1. PMID 25297013.
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 31 (1). WHO. 2017.
- ^ "Pipeline". Alder Biopharmaceuticals.
Template:Protein and peptide receptor modulators
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |